The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-06 and is reviewed periodically as new material appears.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
=== Chemical synthesis === The synthesis of chloramphenicol can be achieved starting from (2R,3S)-2,3-epoxy-3-phenylpropanoic acid methyl ester (derived from methyl cinnamate, step 1 in the synthesis scheme). Upon reaction with sodium nitrite in the presence of acetic acid, the nitrite attacks the epoxide at position 3, producing a nitrite-masked diol (2). Through reaction with diphenyl azidophosphate, diethyl azodicarboxylate, and triphenyl phosphane, the unmasked hydroxyl group at position 2 is substituted by azides (3). Via catalytic hydrogenation using hydrogen over palladium, the azide group is reduced to the amino group, the nitrite ester to the alcohol, and the carboxylic acid ester likewise to the alcohol, resulting in a side chain with one amino and two hydroxy groups (4). The amino group is functionalized with an acetyl group, and the aromatic ring undergoes sulphuric acid/ nitric acid nitration (5). The acetyl group is then removed, and the dichloroacetyl group is introduced using methyldichloroacetate (6).
== Structure == PGLYRP2 has one canonical carboxy-terminal catalytic peptidoglycan-binding type 2 amidase domain (also known as a PGRP domain) with predicted peptidoglycan-binding and catalytic cleft with walls formed by α-helices and the floor by a β-sheet. PGLYRP2 also has a long N-terminal segment that comprises two thirds of the PGLYRP2 sequence, has two hydrophobic regions, is unique and not found in other mammalian PGLYRP1, PGLYRP3, and PGLYRP4 and in invertebrate PGRPs, and contains intrinsically disordered region with hepatitis B virus (HBV) DNA-binding domain. The C-terminal segment is also longer than in other mammalian PGLYRPs. PGLYRP2 has two pairs of cysteines in the PGRP domain that are conserved in all human PGRPs and are predicted to form two disulfide bonds. Human PGLYRP2 is glycosylated and secreted, and forms non-disulfide-linked homodimers. PGLYRP2, similar to all other amidase-active PGRPs (invertebrate and vertebrate), has a conserved Zn2+-binding site in the peptidoglycan-binding cleft, which is also present in bacteriophage type 2 amidases and consists of two histidines, one tyrosine, and one cysteine (His411, Tyr447, His522, Cys530 in human PGLYRP2).
dropping point The temperature at which a grease changes from a semi-solid to a liquid state under standardized conditions, i.e. the upper limit at which the grease retains its structure, though not necessarily the maximum temperature at which it can be used.
== External links == UK New Year Honours List 2024 International list Guernsey Jersey Isle of Man Royal Navy Army Royal Air Force Home Office Police King's Ambulance Medal Overseas Territories Police Medal
=== 2020s === During the COVID-19 pandemic, the company was one of the major developers and processors of COVID-19 testing. In March 2020, Labcorp received emergency use authorization from the FDA for a test for SARS-CoV-2. In April 2020, the company developed the first COVID-19 test in which people were able to collect a sample at home. In July 2020, the company was processing 165,000 COVID-19 tests per day. In December 2021, the company acquired Toxikon, a contract research organization developing non-clinical testing services. In February 2022, the company acquired Personal Genome Diagnostics and its liquid biopsy and tissue-based genomic product, for $450 million in cash plus a possible earn-out of an additional $125 million. Also in February 2022, Labcorp entered into agreements with Ascension, one of the nation’s largest Catholic and nonprofit health systems, to manage Ascension's hospital-based laboratories in ten states and purchase assets of the health system's outreach laboratory business. In June 2023, Labcorp completed the corporate spin-off of Fortrea. In August 2024, Labcorp acquired the assets of bankrupt Invitae for $234 million. In December 2025, Labcorp acquired the ambulatory lab businesses from Community Health Services (CHS) in 13 states for $194 million. In January 2026, it was announced that Labcorp had sold select assets of its early development medical device testing business to NAMSA, a medical device testing, clinical research, and regulatory consulting company.
Sources: en.wikipedia.org
== Commercial peptide synthesis == Peptide synthesis providers are measured by the quality level and the maximum length of the synthesized peptides since it is more difficult to synthesize longer peptides at a high quality. The synthesised peptides must undergo a QC procedure by analytical HPLC and mass spectrometry. Often, amino acid analysis and sequencing is also required.
=== Brand names === Mianserin is marketed in many countries mainly under the brand name Tolvon. It is also available throughout the world under a variety of other brand names including Athymil, Bonserin, Bolvidon, Deprevon, Lantanon, Lerivon, Lumin, Miansan, Serelan, Tetramide, and Tolvin among others.
There are many substances that are purported to have promise in augmenting human cognition by various means. These substances are called nootropics and can potentially benefit individuals with cognitive decline and many different disorders, but may also be capable of yielding results in cognitively healthy persons. Generally speaking, nootropics are said to be effective for enhancing focus, learning, memory function, mood, and in some cases, physical brain development. Some examples of these include Citicoline, Huperzine A, Phosphatidylserine, Bacopa monnieri, Acetyl-L-carnitine, Uridine monophosphate, L-theanine, Rhodiola rosea, and Pycnogenol which are all forms of dietary supplement. There are also nootropic drugs such as the common racetams, e.g. piracetam (Nootropil) and omberacetam (Noopept) along with the neuroprotective Semax, and N-Acetyl Semax. There are also nootropics related to naturally occurring substances but that are either modified in a lab or are analogs such as Vinpocetine and Sulbutiamine. Some authors have explored nootropics as relationship enhancements to help couples maintain bonds over time.
In 2007 a 10-year-old male Dalmatian dog was described with acromegalic signs such as an enlarged tongue and head, widened interdental space, and thickening of skin; along with other signs of hypersomatotropism such as polyphagia, obesity, and stridor. Insulin levels were heightened and the dog had glucose intolerance; however, the dog was not diabetic as blood glucose levels were found to be normal after multiple tests. Levels of IGF-1 and growth hormone were heightened. CT imaging showed a pituitary mass which was later confirmed to be an acidophilic adenoma stained for growth hormone; however, mammary tumour-induced acromegaly is rare with few reported cases. Hypothyroidism can increase levels of growth hormone and IGF-1 in dogs. Some of the physical changes in dogs with hypothyroidism may be due to increased growth hormone concentration.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.